Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?

Expert Rev Gastroenterol Hepatol. 2019 Jan;13(1):1-2. doi: 10.1080/17474124.2019.1543587. Epub 2018 Nov 13.

Authors

Grace Hatton¹, Debbie L Shawcross¹

Affiliation

¹ a Liver Sciences, School of Immunology and Microbial Science, Faculty of Life Sciences and Medicine , King's College London , London , UK.

PMID: 30791837
DOI: 10.1080/17474124.2019.1543587

No abstract available

Keywords: Cirrhosis; faecal microbiota transplantation; gut dysbiosis; gut microbiome; hepatic encephalopathy; immune dysfunction.

Publication types

Editorial

MeSH terms

Animals
Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / therapeutic use*
Bacteria / drug effects*
Bacteria / growth & development
Bacteria / immunology
Dysbiosis
Fecal Microbiota Transplantation* / adverse effects
Gastrointestinal Microbiome / drug effects*
Host-Pathogen Interactions
Humans
Immunity, Innate
Intestines / drug effects*
Intestines / immunology
Intestines / microbiology
Liver Cirrhosis / diagnosis
Liver Cirrhosis / immunology
Liver Cirrhosis / microbiology
Liver Cirrhosis / therapy*
Probiotics / adverse effects
Probiotics / therapeutic use*
Treatment Outcome

Substances

Anti-Bacterial Agents